BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 15476565)

  • 1. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S; Liebson PR; Klein LW
    Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T; Mannella P; Genazzani AR
    Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
    Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of raloxifene: the arterial and venous systems.
    Blumenthal RS; Baranowski B; Dowsett SA
    Am Heart J; 2004 May; 147(5):783-9. PubMed ID: 15131531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
    Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of coronary heart disease in women.
    Rees M; Stevenson J;
    Menopause Int; 2008 Mar; 14(1):40-5. PubMed ID: 18380961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.
    Rossouw JE
    Ann N Y Acad Sci; 2006 Nov; 1089():444-53. PubMed ID: 17261787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Salpeter S
    Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormone replacement in postmenopausal women with coronary heart disease. Results and clinical consequences from recent studies].
    Schurz RA; Benzer W
    Wien Klin Wochenschr; 1997; 109 Suppl 2():42-5. PubMed ID: 9340923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
    Lerman J; Siseles N
    Medicina (B Aires); 2008; 68(3):251-7. PubMed ID: 18689159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.